Pharma & Healthcare

Start with the customer, because that is what separates these businesses. A domestic branded formulations company sells to an Indian patient who was told by a doctor to buy a specific brand. A regulated-market generics company sells to a large American distributor or purchasing group that runs a tender and buys the cheapest compliant supplier. An active pharmaceutical ingredient (API) maker sells to other drug companies. A contract research and manufacturing business sells research and factory capacity to an innovator who owns the molecule. A hospital sells a bed and a procedure. A diagnostics chain sells a test.

Different customers mean different pricing power. Where the buyer is one person following a doctor's advice, price is sticky. Where the buyer is a procurement department with four approved suppliers on a list, price falls every year by design. Same sector, opposite economics.

This is why an index move tells you very little. A day when the pharma index is up can be a day when export-heavy names rose on a currency move while a hospital chain fell on a quarterly occupancy number. The sector average is an average of unrelated things.

Read this table first. Almost every argument on this page follows from the fact that these six columns disagree with each other.

In India, off-patent medicines are still sold as brands. Two companies can sell the same molecule at different prices, and both sell, because the doctor writes a brand on the prescription and the patient buys what is written. That single fact turns a technically generic product into a consumer business with a distribution moat.

The moat is the field force. A medical representative visits doctors in a territory, month after month, and builds the habit. Replacing that relationship is slow and expensive, which is why domestic formulations revenue is unusually predictable. Chronic therapies — diabetes, cardiac, respiratory — are the best version of it, because the patient refills the same prescription for years. Acute therapies such as anti-infectives are lumpier and seasonal.

Growth in this business decomposes cleanly into three parts: volume (more patients or more packs), new introductions (molecules or combinations launched this year), and price (small, and capped by policy on part of the portfolio). Companies disclose this split. When you see it, you can tell a business growing on patients from one growing only on price. Sun Pharma, Cipla, Torrent and Mankind all run large domestic branded books; the size of that book relative to exports is the first thing to check on any Indian pharma company.

The export generics business works differently and the difference is structural, not cyclical. A patent expires. Several companies file to sell a copy. The earliest filers may get a limited exclusivity window in the United States, during which few suppliers compete and the price holds up. After that window, more approvals arrive and the buyers — a small number of very large distributors and pharmacy groups — run the price down.

So the base case for any single product in this business is that its price falls every year. Not in a bad year. Every year. The industry's word for it is price erosion, and it is the reason a generics company must keep launching new products simply to hold revenue flat. Growth requires the new-launch contribution to exceed the erosion on the existing book.

This is also why the market pays a lower multiple for export generics revenue than for domestic branded revenue. It is not a judgement about quality. It is arithmetic about durability.

Because existing products erode, the honest forward indicator in a generics business is the pipeline: how many applications have been filed, how many are still pending approval, how many were approved this year, and how many of those were actually launched. Filings are cheap to announce and slow to convert. Approvals are the real event. Launches are the revenue.

Companies disclose these counts in investor presentations and annual reports, and the American regulator publishes approval data publicly, so you can verify the claim rather than take it. What you are looking for is the shape: a pipeline that is growing, skewed towards complex products, and converting into launches — versus one that is large but stuck at 'filed'.

Complexity matters more than count. A simple oral tablet that fifteen companies can make erodes fast. An injectable, an inhaler, a transdermal patch or a peptide has fewer capable suppliers, so the price holds longer. One approval in a hard-to-make category can be worth more than ten in an easy one.

A drug sold in the United States or Europe must be made at a site that the importing country's regulator has inspected and accepted. That inspection is periodic, unannounced in practice, and its outcome is close to binary. A clear outcome means nothing changes. An adverse outcome — written observations, an escalation to a warning letter, or in the worst case a restriction on importing from that site — can stop shipments of every product made there, including products that were approved years ago and were selling perfectly well.

Read that again, because it is the part most readers miss: the risk attaches to the factory, not to the product. One site can carry a dozen products across several therapy areas. If the site is restricted, all of them are affected at once, and the fix is a remediation programme that takes quarters, sometimes years, plus a re-inspection.

This is what makes the pharma sector genuinely different from a risk point of view. A rate cut hits every bank. A monsoon hits every tractor maker. A plant inspection hits exactly one company, and owning five pharma names does not average it out — it just gives you five separate chances to be exposed to one.

The domestic business has a permanent policy input. India maintains a National List of Essential Medicines (NLEM), and medicines on that list have a ceiling price set by the National Pharmaceutical Pricing Authority (NPPA). Formulations outside the list can raise price only within an annual cap linked to wholesale price inflation. The practical effect is that a chunk of every domestic portfolio has a policy-set price ceiling, and when the essential list is expanded, molecules move from the free bucket into the capped bucket.

This is not a catastrophe and it is not nothing. It caps the price lever, which pushes companies to grow on volume and on new combinations instead. When you read a domestic growth number, it helps to know what share of that portfolio is under price control, because it tells you how much of future growth has to come from patients rather than pricing.

The second variable runs the other way. India makes a very large share of the world's finished generic medicines, but has historically imported a large share of its key starting materials and several bulk ingredients from China. After the supply shocks of recent years, both global buyers and the Indian government pushed for a second source — the shorthand is 'China plus one'. Production-linked incentive schemes for bulk drugs are the policy expression of it. The direction is real and structural. The timeline is slow: building ingredient capacity is capital-heavy, the imported cost base is genuinely low, and a new plant still has to be qualified by its customers.

A hospital is a fixed-cost business wearing a healthcare label. The building, the equipment, the nursing staff and the electricity are largely there whether the beds are full or empty. Below a break-even level of occupancy the hospital loses money; above it, a very large share of each incremental rupee drops to profit. That is why occupancy is the first number in every hospital results release.

The second number is average revenue per occupied bed (ARPOB) — what one filled bed earns per day. It rises with case mix, not with volume: a complex cardiac or oncology procedure earns far more per bed-day than a general ward admission. A chain improving ARPOB without adding beds is changing what it treats. The third number is average length of stay, which cuts the other way — shorter stays free the bed for the next patient, so falling length of stay with rising ARPOB is a genuine efficiency gain rather than a price increase.

The hard part is gestation. A new hospital needs land, construction, approvals, equipment, and then the slow work of attracting senior doctors and building a referral flow. That takes years, and during those years the new unit carries depreciation, interest and salaries against thin revenue. A chain expanding aggressively will therefore show diluted margins before it shows growth. Chains that disclose mature units separately from new units are handing you the tool to read this properly.

Diagnostics runs on different physics. The marginal cost of one more test on an already-running analyser is small, so gross margins are structurally high and the whole fight is upstream: acquiring the patient and holding the price. A hub-and-spoke network with collection centres feeding a central lab spreads the fixed cost, and the metrics to watch are samples per patient, revenue per patient and the number of active collection points. The recurring risk is a discounting war, because a well-funded new entrant can buy volume by cutting price and gross margin compresses across the whole sector while it lasts.

Different sub-segments react to different calendars. Knowing which release is relevant to which business saves you from reading the wrong number.